Michael Recht, M.D., Ph.D., M.B.A.

  • Professor of Pediatrics, Division of Hematology and Oncology, School of Medicine
  • Chief Science Officer, American Thrombosis and Hemostasis Network

Biography

Dr. Michael Recht specializes in caring for children, adolescents and young adults with bleeding and clotting disorders. He has been a part of more than 100 clinical research trials testing new treatments for children and adults with bleeding and clotting disorders. He has also been a leader in research into gene therapy for hemophilia.

Dr. Recht was the director of the Hemophilia Center at OHSU from 2007 until 2020. He was also director of the Mountain States Hemophilia Network, a collaboration of hemophilia treatment centers in the western United States. He currently serves as the Chief Science Officer for the American Thrombosis and Hemostasis Network, a nonprofit organization dedicated to improving the lives of people affected by bleeding and clotting disorders.

When he's not working, Dr. Recht enjoys spending time with his wife, two young adult daughters and three dogs. He is an avid skier. During the few months when snow doesn't cover the blue and green trails on Mt. Hood, he can be found at any coast or shore.

Education and training

    • B.S., 1987, University of Wisconsin
    • Ph.D., 1990, University of Wisconsin
    • M.D., 1992, University of Wisconsin
    • M.B.A., 2016, Oregon Health & Science University/ Portland State University

  • Residency

    • Pediatrics, Yale New Haven Hospital, Yale University, 1995

  • Fellowship

    • Fellowship in pediatric hematology-oncology, Yale University School of Medicine, 1998

Memberships and associations:

  • American Thrombosis and Hemostasis Network
  • Foundation for Women and Girls with Blood Disorders
  • American Society of Hematology
  • Hemophilia and Thrombosis Research Society
  • International Society on Thrombosis and Hemostasis
  • American Society of Pediatric Hematology-Oncology
  • National Hemophilia Foundation
  • American Board of Pediatrics, sub-board of Pediatric Hematology/Oncology

Areas of interest

  • Care of children, adolescents, and young adults with bleeding and clotting disorders
  • Long term studies examining the safety and effectiveness of current and novel therapies for bleeding and clotting disorders
  • Gene therapy for hemophilia

Additional information

Publications

Elsevier pure profile

Selected publications

  • The critical need for postmarketing surveillance in gene therapy for?haemophilia. Konkle BA, Recht M, Hilger A, Marks P. Haemophilia. 2020 Jun 3. Online ahead of print. PMID:?32495492
  • Emicizumab in?Hemophilia?A. Buckner TW, Watson C, Recht M.N Engl J Med. 2020 Feb 20;382(8):785-786. PMID:?32074441
  • The national blueprint for 21st century data and specimen collection and observational cohort studies: NHLBI State of the Science Workshop on factor VIII inhibitors. Konkle BA, Recht M; members of Working Group 2, the NHLBI State of the Science Workshop on factor VIII inhibitors: Generating a national blueprint for future research. Haemophilia. 2019 Jul;25(4):590-594. PMID:?31329362

Publications

  • {{ pub.journalAssociation.journal.name.text[0].value }}